Attovia Therapeutics (NASDAQ:ATTO) Research Coverage Started at Citigroup

by · The Markets Daily

Citigroup initiated coverage on shares of Attovia Therapeutics (NASDAQ:ATTO – Free Report) in a research report sent to investors on Monday, MarketBeat reports. The brokerage issued a buy rating and a $30.00 target price on the stock.

A number of other analysts also recently commented on ATTO. Morgan Stanley started coverage on Attovia Therapeutics in a research note on Monday. They issued an “overweight” rating and a $39.00 target price on the stock. Leerink Partners assumed coverage on Attovia Therapeutics in a report on Monday. They issued an “outperform” rating and a $52.00 price target for the company. Five equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $42.20.

Get Our Latest Report on Attovia Therapeutics

Attovia Therapeutics Price Performance

NASDAQ ATTO opened at $23.13 on Monday. Attovia Therapeutics has a 1 year low of $16.15 and a 1 year high of $24.32.

Attovia Therapeutics (NASDAQ:ATTO – Get Free Report) last announced its quarterly earnings results on Wednesday, September 2nd. The company reported ($4.88) earnings per share for the quarter.

Insiders Place Their Bets

In other Attovia Therapeutics news, major shareholder Global Strategic Fund I. Venbio purchased 382,352 shares of the business’s stock in a transaction that occurred on Thursday, August 6th. The stock was purchased at an average price of $17.00 per share, for a total transaction of $6,499,984.00. Following the purchase, the insider directly owned 4,181,367 shares in the company, valued at approximately $71,083,239. This trade represents a 10.06% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Colin Walsh purchased 500,000 shares of the business’s stock in a transaction that occurred on Thursday, August 6th. The stock was acquired at an average price of $17.00 per share, with a total value of $8,500,000.00. Following the purchase, the director owned 3,020,632 shares in the company, valued at $51,350,744. This represents a 19.84% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have acquired 2,740,587 shares of company stock valued at $47,269,979. Insiders own 0.99% of the company’s stock.

Key Headlines Impacting Attovia Therapeutics

Here are the key news stories impacting Attovia Therapeutics this week:

  • Positive Sentiment: Positive ATTO-1310 clinical update: Attovia reported preliminary proof of concept for ATTO-1310 in chronic pruritus and high-itch atopic dermatitis. Complete Phase 1b data are expected in the fourth quarter of 2026, providing a near-term catalyst. Attovia Therapeutics second-quarter results and corporate update
  • Positive Sentiment: New bullish analyst coverage: LifeSci Capital initiated coverage with an “outperform” recommendation. Citigroup, Leerink Partners and Royal Bank of Canada also began coverage, increasing institutional visibility around the biotech. LifeSci Capital coverage
  • Positive Sentiment: Royal Bank of Canada recently upgraded Attovia to “moderate buy,” reinforcing the positive analyst sentiment surrounding the company’s pipeline. Royal Bank of Canada upgrade
  • Neutral Sentiment: Attovia’s second-quarter earnings release provides investors with an updated financial and corporate overview, with attention likely focused on development spending and the company’s ability to fund upcoming clinical work. Attovia Therapeutics earnings press release
  • Negative Sentiment: Widening quarterly loss: Attovia reported a second-quarter loss of $4.88 per share, while separate coverage characterized the company’s net loss as wider than in the prior-year period. Continued losses could weigh on the stock if investors become concerned about cash needs or execution risk. Attovia Therapeutics Q2 net loss

Attovia Therapeutics Company Profile

(Get Free Report)

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.

Featured Articles